Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00109798

Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

Phase II Trial of Salvage Chemotherapy With Temozolomide in Combination With Topotecan for Primary CNS Lymphoma

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
The Methodist Hospital Research Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide and topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving temozolomide together with topotecan works in treating patients with primary CNS lymphoma.

Detailed description

OBJECTIVES: Primary * Determine the complete radiologic response rate in patients with primary CNS lymphoma treated with salvage chemotherapy comprising temozolomide and topotecan. Secondary * Determine the median and failure-free survival of patients treated with this regimen. * Determine the toxicity of this regimen in these patients. * Determine the overall response rate in patients treated with this regimen. OUTLINE: This is an open-label study. Patients receive oral temozolomide once daily on days 1-5 and topotecan IV over 30 minutes once daily on days 2-6. Treatment repeats every 28 days for 6-8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 6-25 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGtemozolomidePatient will take drug on day 1-5 of 28 day schedule
DRUGtopotecan hydrochloridePatient will have IV on days 2-6 on a 28-day schedule

Timeline

Start date
2005-03-01
Primary completion
2006-07-01
Completion
2006-07-01
First posted
2005-05-04
Last updated
2017-09-19

Source: ClinicalTrials.gov record NCT00109798. Inclusion in this directory is not an endorsement.